Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership

Executive Summary

Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.

You may also be interested in...



Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m

While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.

Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders

The rare disease specialist gained 10 gene therapy programs with the acquisition of Celenex, including two in clinical-stage development for Batten disease, in exchange for $100m up front. President Bradley Campbell talked to Scrip about the process that led to the deal and next steps for development.

Sobi Loses Private Equity Buyout

An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel